SNY Sanofi

Healthcare · Drug Manufacturers - General

5 · Correct Momentum 7.0 · Neutre À risque série de 3 a

48.40

+0.34%

À propos de l'entreprise

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Site web

5.00% prévisionnel

120.40%

5.00% 2.42 USD

2.42

116.0B

24.08

2.01

44.33

Plage 52 semaines

48.4

bas 39.1 haut 52.7

Analyse approfondie du dividende

Sanofi (SNY) is an equity with a current dividend yield of 5.01%. The company's dividend yield compared to its 5-year historical band, including its average, low, and high points, is not available. The dividend safety status, momentum score, and value score for Sanofi are also not provided in the data. With a market capitalization of 115,685,515,264.0 USD, Sanofi operates as a large-cap company at a current price of 48.28 USD.

Historique des dividendes

The data provided does not include details on Sanofi's dividend growth streak, making it impossible to ascertain consecutive years of increases. Furthermore, the 3-year and 5-year dividend Compound Annual Growth Rates (CAGR) are not available. A year-by-year breakdown of past dividend payments is also missing, which prevents a detailed analysis of its historical consistency. The market data indicates an annual dividend of 2.42 USD per share, contributing to the current dividend yield of 5.01%. Without historical dividend payment information, growth trends cannot be evaluated.

Sécurité du dividende

Sanofi's dividend coverage appears challenged with a payout ratio of 120.4%, indicating the company paid out more in dividends (2.42 USD per share) than it earned in EPS (2.01 USD per share).

Quantic · Gratuit

Lis la suite de la sécurité du dividende

Avec les risques clés et ce qu'il faut surveiller ensuite. Gratuit, sans carte.

Essayer un portefeuille d'exemple S'inscrire gratuitement

Généré par IA à partir des données de dividendes de Quantic · Mis à jour le 11 Nov 2026 · À titre informatif uniquement — pas un conseil financier.

Affiché en anglais — une traduction arrive.